Inhibition of serine/threonine-protein kinase B-Raf (BRAF) and mitogen-activated protein kinase (MEK) in combination with A2AR provided a significant reduction of tumor progression and metastasis formation in a melanoma mouse model [58]. Here, BRAF is linked to melanoma.